1. Home
  2. CCG vs EQ Comparison

CCG vs EQ Comparison

Compare CCG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCG

Cheche Group Inc.

HOLD

Current Price

$0.79

Market Cap

69.5M

Sector

N/A

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.49

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCG
EQ
Founded
2014
2017
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.5M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CCG
EQ
Price
$0.79
$1.49
Analyst Decision
Buy
Hold
Analyst Count
1
1
Target Price
$350.00
$1.00
AVG Volume (30 Days)
90.1K
518.9K
Earning Date
03-30-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$444,290,042.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.27
52 Week High
$1.54
$2.35

Technical Indicators

Market Signals
Indicator
CCG
EQ
Relative Strength Index (RSI) 35.31 61.93
Support Level $0.78 $1.17
Resistance Level $0.83 $1.57
Average True Range (ATR) 0.03 0.12
MACD -0.00 0.03
Stochastic Oscillator 18.70 86.54

Price Performance

Historical Comparison
CCG
EQ

About CCG Cheche Group Inc.

Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: